The Usage of Cryopreserved Reproductive Material in Cancer Patients Undergoing Fertility Preservation Procedures

Author:

Wnuk Katarzyna12ORCID,Świtalski Jakub3ORCID,Miazga Wojciech12ORCID,Tatara Tomasz14ORCID,Religioni Urszula2ORCID,Olszewski Paweł5,Augustynowicz Anna3

Affiliation:

1. Department of Health Policy Programs, Department of Health Technology Assessment, Agency for Health Technology Assessment and Tariff System, 00032 Warsaw, Poland

2. School of Public Health, Centre of Postgraduate Medical Education of Warsaw, Kleczewska 61/63, 01826 Warsaw, Poland

3. Department of Health Economics and Medical Law, Faculty of Health Sciences, Medical University of Warsaw, 01445 Warsaw, Poland

4. Department of Public Health, Faculty of Health Sciences, Medical University of Warsaw, 02091 Warsaw, Poland

5. Medical Faculty, Lazarski University, 02662 Warsaw, Poland

Abstract

Background: Many cancer treatment methods can affect fertility by damaging the reproductive organs and glands that control fertility. Changes can be temporary or permanent. In order to preserve the fertility of cancer patients and protect the genital organs against gonadotoxicity, methods of fertility preservation are increasingly used. Considering that some patients ultimately decide not to use cryopreserved reproductive material, this review analysed the percentage of post-cancer patients using cryopreserved reproductive material, collected before treatment as part of fertility preservation. Methods: A systematic search of studies was carried out in accordance with the Cochrane Collaboration guidelines, based on a previously prepared research protocol. The search was conducted in Medline (via PubMed), Embase (via OVID), and the Cochrane Library. In addition, a manual search was performed for recommendations/clinical practice guidelines regarding fertility preservation in cancer patients. Results: Twenty-six studies met the inclusion criteria. The studies included in the review discussed the results of cryopreservation of oocytes, embryos, ovarian tissue, and semen. In 10 studies, the usage rate of cryopreserved semen ranged from 2.6% to 21.5%. In the case of cryopreserved female reproductive material, the return/usage rate ranged from 3.1% to 8.7% for oocytes, approx. 9% to 22.4% for embryos, and 6.9% to 30.3% for ovarian tissue. In studies analysing patients’ decisions about unused reproductive material, continuation of material storage was most often indicated. Recovering fertility or death of the patient were the main reasons for rejecting cryopreserved semen in the case of men. Conclusion: Fertility preservation before gonadotoxic treatment is widely recommended and increasingly used in cancer patients. The usage rate is an important indicator for monitoring the efficacy of these methods. In all of the methods described in the literature, this indicator did not exceed 31%. It is necessary to create legal and organizational solutions regulating material collection and storage and to create clear paths for its usage in the future, including by other recipients.

Funder

Medical University of Warsaw

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference72 articles.

1. World Health Organization (2023, June 13). ICD-11 for Mortality and Morbidity Statistics (Version: 01/2023). Female Infertility, Available online: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1237004558.

2. International Agency for Research on Cancer (World Health Organization) (2023, June 13). ICD-11 for Mortality and Morbidity Statistics (Version: 01/2023). Male Infertility, Available online: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/753457327.

3. (2023, June 13). Estimated Number of New Cases in 2020, World, Both Sexes, Ages 15–49. Available online: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=3&ages_group%5B%5D=9&group_cancer=1&include_nmsc=1&include_nmsc_other=1.

4. Hao, X., Anastácio, A., Liu, K., and Rodriguez-Wallberg, K.A. (2019). Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review. Int. J. Mol. Sci., 20.

5. Demeestere, I., Moffa, F., Peccatori, F., Poirot, C., and Shalom-Paz, E. (2012). Multiple Approaches for Individualized Fertility Protective Therapy in Cancer Patients. Obstet. Gynecol. Int., 2012.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3